INTARCIA THERAPEUTICS
Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.
INTARCIA THERAPEUTICS
Industry:
Biotechnology Health Care Health Diagnostics Medical Device Personal Health
Founded:
1997-01-01
Address:
Hayward, California, United States
Country:
United States
Website Url:
http://www.intarcia.com
Total Employee:
251+
Status:
Active
Contact:
617-936-2500
Total Funding:
1.68 B USD
Technology used in webpage:
Domain Not Resolving Euro IPv6 Amazon Route 53 Microsoft Apple Whitelist
Similar Organizations
Advanced Animal Diagnostics
Advanced Animal Diagnostics develops diagnostic products to cure on-farm animal diseases.
Aerin Medical
Aerin Medical is a health technology company that develops therapeutic devices to improve nasal breathing.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Alcresta
Alcresta develops enzyme-based nutritional products for infants and adults with acute and chronic diseases.
American Renal Associates Holdings
American Renal Associates Holdings operates kidney dialysis services and offers outpatient and inpatient dialysis treatments.
Ancora Heart
Ancora Heart is dedicated to helping people with heart failure feel better and live longer.
SpaceOAR
SpaceOAR is a medical device company that develops space-filling hydrogels for radiation oncology and cancer surgery indications.
Binx Health
Binx Health creates new categories of healthcare solutions that deliver on-demand testing to people where they need it most.
Butterfly Network
Butterfly Network designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Daktari Diagnostics
Daktari Diagnostics manufactures diagnostic medical products for clinicians and patients.
Elcelyx Therapeutics
Elcelyx Therapeutics is developing nutrient sensing-based products for weight management and obesity-related metabolic disorders.
Enzium
Enzium develops fluorescent based reagents for selective protease.
Galera Therapeutics
Galera Therapeutics develops therapeutic agents for preventing damage to normal tissues during the radiation treatment of cancer.
Forward
Forward is a healthcare startup that provides a membership-based health care system.
Humacyte
Humacyte develops products for vascular diseases and replacement of anatomical conduits.
ImaginAb
ImaginAb clinically manages cancer and autoimmune diseases via molecular imaging by re-engineering antibodies into small proteins.
Impliant
Impliant, Inc. develops novel spine arthroplasty solutions for motion preservation. The company offers TOPS system.
Injectsense
Monitoring therapy effectiveness (glaucoma) through miniaturized, autonomous in-vivo sensing and data uploading to cloud database.
iPierian
iPierian is a drug discovery platform that develops therapies for neurodegenerative diseases such as SMA, ALS, and Parkinson’s.
Ivantis
Ivantis is focused on developing an innovative treatment for glaucoma which includes eye drops, laser therapy, and surgery.
jCyte
jCyte is a developer of cell-based technology intended to cure retinitis pigmentosa.
Moximed
Moximed improves the standard of care for patients with osteoarthritis and investigates therapies to treat affected joints.
Opus Genetics
Opus Genetics is a gene therapy company for ultra-rare blinding conditions.
Oxford Immunotec
Oxford Immunotec, a medical diagnostics company, develops tests for various diseases based on its innovative T cell measurement technology.
OxSonics Therapeutics
OxSonics® Therapeutics’ proprietary drug delivery platform technology, SonoTran®
Prima Temp
Prima Temp specializes in fertility detection, early disease detection, and circadian rhythm monitoring.
Amelia Virtual Care
Amelia Virtual Care develops a virtual reality platform designed to bring value to mental health treatment.
CardiacSense
CardiacSense is a developer of a wearable technology for continuous cardiac arrhythmia detection and non-inflating blood pressure monitoring
Syndevrx
SynDevRx develops polymer-based drug conjugates for small molecule drug activity.
UE LifeSciences
UE LifeSciences is a female technology company building preventive oncology solutions for primary care and home.
Unicycive Therapeutics
Unicycive Therapeutics provides development programs that focus on treating kidney diseases with unmet medical needs.
Aspira Women's Health
Aspira Women's Health develops and commercializes diagnostic tests that address unmet needs in gynecologic oncology and women’s health.
Know Labs
Know Labs is a non-invasive diagnostic technology platform that uses radio waves to identify and measure molecules in the body.
Vivos Therapeutics
Vivos Therapeutics is a medical research and development company focused on breathing wellness.
Current Advisors List
Board_member
2013-12-01
Board_member
2013-06-01
Board_member
2003-06-01
Board_member
2017-09-19
Board_member
2010-08-01
Board_member
2017-09-19
Board_member
2017-09-19
Board_member
2017-09-19
Current Employees Featured
Thomas Alessi Vice President, Development and Manufacturing @ Intarcia Therapeutics
Vice President, Development and Manufacturing
1997-12-01
David Franklin Vice President, Commercial Operations @ Intarcia Therapeutics
Vice President, Commercial Operations
2015-05-01
Sunita Zalani Vice President, Global Regulatory Affairs and Quality @ Intarcia Therapeutics
Vice President, Global Regulatory Affairs and Quality
2014-05-01
Andrew Young Vice President & Chief Scientific Officer @ Intarcia Therapeutics
Vice President & Chief Scientific Officer
2015-09-01
Owen Hughes, Jr Chief Business Officer and Head of Corporate Development @ Intarcia Therapeutics
Chief Business Officer and Head of Corporate Development
2013-02-01
Jay Smith CXO- Chief Experience Officer- Head of Customer experience and Outcomes @ Intarcia Therapeutics
CXO- Chief Experience Officer- Head of Customer experience and Outcomes
2013-12-01
Dick Ford Executive Director, DUROS® Manufacturing @ Intarcia Therapeutics
Executive Director, DUROS® Manufacturing
2006-08-01
Fred T. Fiedorek Chief Medical Officer and Global Head of Regulatory Affair @ Intarcia Therapeutics
Chief Medical Officer and Global Head of Regulatory Affair
Kurt Graves President & CEO @ Intarcia Therapeutics
President & CEO
2010-08-01
David Spellman Chief Financial & Chief Business Officer @ Intarcia Therapeutics
Chief Financial & Chief Business Officer
2019-11-01
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2015-09-24 | Phoundry Pharmaceuticals | Phoundry Pharmaceuticals acquired by Intarcia Therapeutics | N/A |
Investors List
GGV Capital
GGV Capital investment in Venture Round - Intarcia Therapeutics
SharesPost Investment Management
SharesPost Investment Management investment in Secondary Market - Intarcia Therapeutics
GWC Innovator Fund
GWC Innovator Fund investment in Series E - Intarcia Therapeutics
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Series E - Intarcia Therapeutics
The Pritzker Organization
The Pritzker Organization investment in Series E - Intarcia Therapeutics
Foresite Capital
Foresite Capital investment in Series E - Intarcia Therapeutics
The Baupost Group
The Baupost Group investment in Series E - Intarcia Therapeutics
RA Capital Management
RA Capital Management investment in Series E - Intarcia Therapeutics
Baillie Gifford
Baillie Gifford investment in Series E - Intarcia Therapeutics
Kayon Partners
Kayon Partners investment in Series E - Intarcia Therapeutics
Official Site Inspections
http://www.intarcia.com
- Host name: ec2-52-20-84-62.compute-1.amazonaws.com
- IP address: 52.20.84.62
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Intarcia Therapeutics"
Intarcia Therapeutics - Crunchbase Company Profile
Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug …See details»
Intarcia Therapeutics - Wikipedia
Intarcia Therapeutics is an American biopharmaceutical company based in Boston, MA and incorporated under the laws of Delaware. It was founded in 1995 under the name "BioMedicines" and changed to its present name in 2004. In 2013, Intarcia relocated its headquarters to Boston, keeping its manufacturing facility in Hayward, CA. In addition to Boston and Hayward, Intarcia also has a location in Research Triangle Park, North Carolina, where it discovers and develops …See details»
Intarcia Therapeutics, Inc. - LinkedIn
Intarcia Therapeutics, Inc. | 11,844 followers on LinkedIn. We operate with a “No Analog” mindset—continually pushing boundaries, navigating new terrain and unleashing fresh thinking. We are ...See details»
Intarcia 2025 Company Profile: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for Intarcia. Use the PitchBook Platform to explore the full profile.See details»
Intarcia Therapeutics, Inc. | Devex
Learn more about Intarcia Therapeutics, Inc.'s jobs, projects, latest news, contact information and geographical presence. Intarcia Therapeutics, Inc., is a rapidly emerging biopharmaceutical ...See details»
Intarcia Therapeutics, Inc. Company Profile | Cambridge, MA ...
Intarcia Therapeutics, Inc. is a biopharmaceutical company dedicated to improving real-world adherence and real-world outcomes by leveraging the convergence of medicines and novel …See details»
Intarcia Therapeutics, Inc. | (510) 782-7800 | Hayward, California
Intarcia Therapeutics, Inc. is a biopharmaceutical company that offers a range of services in addition to its proprietary products. These services include research and development, …See details»
Intarcia Therapeutics - Leadership Team | The Org
The Leadership Team at Intarcia Therapeutics is responsible for guiding the company's strategic vision and operational execution in the development of innovative therapies for chronic …See details»
Intarcia Therapeutics Company Information - Funding, Investors, …
Get information on funding, investors, industries, and more for Intarcia Therapeutics. See Intarcia Therapeutics company profile and funding data.See details»
Intarcia Therapeutics - Contacts, Employees, Board Members, …
Intarcia Therapeutics has 9 current employee profiles, including Vice President, Global Regulatory Affairs and Quality Sunita Zalani. Intarcia Therapeutics has 7 board members and advisors, …See details»
Intarcia Therapeutics - VentureRadar
"Intarcia Therapeutics, Inc. is a biopharmaceutical company dedicated to improving real-world adherence and real-world outcomes in some of our nation’s most costly and devastating …See details»
Intarcia, a former biotech unicorn, gets new life with startup deal
Aug 30, 2023 Former biotechnology unicorn Intarcia Therapeutics is getting a new life less than a month before a panel of Food and Drug Administration advisers could decide the fate of the …See details»
Intarcia Therapeutics - Funding, Financials, Valuation & Investors
Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.See details»
Intarcia Therapeutics: Revenue, Worth, Valuation & Competitors …
About Intarcia Therapeutics Intarcia Therapeutics is a Biotech related company founded in 1997 and based in Boston with 105 employees an estimated revenue of $16.3M, and. It has 10 …See details»
FDA panel votes down Intarcia's twice-rejected, long-term …
Sep 22, 2023 In its 2020 complete response letter rejecting the company’s application, the FDA urged Intarcia to redesign the product to make the drug-release rates more reliable and to then …See details»
Intarcia Therapeutics's Revenue, Funding, Employees & Business …
Intarcia Therapeutics is a biopharmaceutical company that develops innovative therapies to help improve the lives of people living with chronic diseases. The company focuses on developing …See details»
ABOUT US – Intarcia Life Sciences
Welcome to Intarcia Life Science, a trusted name in healthcare and wellness solutions. Our mission is to enhance lives by providing innovative, high-quality health products and services …See details»
i2o Therapeutics acquires Intarcia Therapeutics - 2023-08-28 ...
Aug 28, 2023 Intarcia Therapeutics Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.See details»
Intarcia Therapeutics Careers | Levels.fyi
Intarcia is a biotech company committed to creating meaningful impact in business, health, and society by redesigning the treatment, prevention, and experience of chronic diseases.See details»
Once valued at more than $5B, Intarcia Therapeutics sees all of its ...
Aug 31, 2022 Once valued at more than $5B, Intarcia Therapeutics sees all of its execs depart and its final shot at FDA deniedSee details»